IgY Antibody Detection of MERS-CoV N Protein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunodiagnostic tests for MERS-CoV face challenges such as cross-reactivity, interference from mammalian proteins, and low specificity due to the use of mammalian antibodies, leading to false positive and false negative results, and lack of recognition of important epitopes by mammalian immune systems.
Innovation Solution
Development of IgY antibodies from chickens, which offer higher specificity and sensitivity for detecting MERS-CoV N protein epitopes, using polyclonal or monoclonal preparations that recognize specific peptide segments or domains of the N protein, reducing interactions with mammalian immune components and enhancing binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If mammalian antibodies are used for immunodiagnostic testing, then the test can be performed with standard mammalian immunology techniques, but cross-reactivity and interference from mammalian proteins occur leading to false positive results
Solution Approach 1:
The patent uses avian IgY antibodies as an intermediary detection tool that bridges the gap between the mammalian sample and the detection system. These IgY antibodies recognize MERS-CoV antigens without cross-reacting with mammalian proteins, thereby eliminating false positives while maintaining ease of manufacture through established avian immunization protocols
Solution Approach 2:
The patent changes the species parameter of the antibody from mammalian to avian, fundamentally altering the immunological interaction parameters. This species switch transforms the antibody repertoire to eliminate cross-reactivity with mammalian proteins while maintaining specificity for MERS-CoV, resolving the contradiction between ease of manufacture and reliability
2Ease of manufacture
If mammalian antibodies are used for immunodiagnostic testing, then the test can be performed with standard techniques, but interference from mammalian immune components occurs leading to false negative results
Solution Approach 1:
Avian IgY antibodies serve as an intermediary that detects MERS-CoV antigens without being interfered with by mammalian immune components. This eliminates false negatives caused by interference from rheumatoid factor, complement components, or Fc receptors, while maintaining ease of manufacture through standard avian immunization and egg yolk recovery protocols
Solution Approach 2:
The patent changes the immunological parameter of antibody species from mammalian to avian, which fundamentally alters the interaction profile. This parameter change eliminates interference from mammalian immune components, thereby improving sensitivity and measurement precision while maintaining ease of manufacture
3Reliability
If antibodies to S protein are used for detection, then the test targets a surface exposed antigen, but specificity is reduced due to amino acid sequence variation leading to false negative results
Solution Approach 1:
The patent applies local quality by targeting specific conserved epitopes on the N protein that are locally optimized for antibody recognition. The N protein epitopes identified are those that are both conserved across MERS-CoV strains and highly recognizable by avian IgY antibodies, thereby simultaneously improving specificity and sensitivity
Solution Approach 2:
The patent changes the target antigen parameter from S protein to N protein, and the antibody species parameter from mammalian to avian. This dual parameter change results in antibodies that recognize conserved epitopes across strains, eliminating false negatives while maintaining high specificity
4Measurement precision
If RT-RCR is used for diagnosis, then high sensitivity and specificity are achieved, but specialized equipment and molecular skills are required making it unsuitable for point-of-care testing
Solution Approach 1:
The patent substitutes the complex molecular mechanics of RT-RCR with a simpler immunological detection system. By replacing nucleic acid amplification and detection with antibody-based antigen detection, the system maintains high specificity while dramatically simplifying the operational requirements for point-of-care testing
Solution Approach 2:
The patent changes the detection parameter from molecular (nucleic acid) to immunological (antibody-antigen binding). This parameter change transforms the test from requiring specialized molecular equipment and skills to a simpler system that can be performed with standard immunological techniques at the point of care
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IgY-based assays provide a more accurate and sensitive detection of MERS-CoV, with the ability to recognize a broader range of epitopes and minimize false positives, enabling rapid and reliable diagnosis at the point of care or in laboratory settings.
Implementation Method 1
contacting the sample with an IgY antibody that recognizes MERS-CoV N protein and detecting complex formation or binding of the IgY to the MERS-CoV
Data Source
AI summary
A method for detecting MERS-CoV at high sensitivity and specificity using IgY antibodies that bind to MERS-CoV N protein, its fragments and domains. Isolated or purified IgY monospecific antibodies to MERS-CoV N protein.